Skip to main content
. Author manuscript; available in PMC: 2013 Jul 19.
Published in final edited form as: Cancer Discov. 2013 Mar 21;3(4):418–429. doi: 10.1158/2159-8290.CD-12-0383

Figure 1.

Figure 1

MART-1TCR transgenic T-cell ACT therapy. A, the boxes above the timeline show different modules of the therapy, with arrows pointing to the time they are administered relative to day 0 (the day of the infusion of the TCR-engineered T cells). Arrows below the timeline show the dates when blood samples are collected for different assays. B, photo of one representative patient’s back with skin rash surrounding moles (top). In the immunohistochemical (IHC) staining of a tumor biopsy (bottom), CD8+ CTLs are stained as dark brown and melanoma cells are blue. PET/CT, positron emission tomography/computed tomography.